

March 31, 2025

PDRadiopharma Inc.

PDRadiopharma Host Joint Seminar at The 84th Annual Meeting of the Japanese Society, and Exhibit at the International Technical Exhibition of Medical Imaging 2025

TOKYO, JAPAN – March 31, 2025 – PDRadiopharma Inc.(President and CEO: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, “PDRadiopharma”) will jointly host a seminar at the 84th Annual Meeting of the Japan Radiological Society, taking place from April 10 to 13, 2025, at PACIFICO Yokohama.

Additionally, during the International Technical Exhibition of Medical Imaging 2025 (ITEM 2025), to be held at the same venue from April 11 to 13, PDRadiopharma will present our latest products at an exhibition booth.

The seminar and exhibition booth will highlight PDRadiopharma's commitment to advancing healthcare through innovative radiopharmaceutical solutions, offering attendees a closer look at the technologies shaping the future of nuclear medicine.

【Information on the joint seminar】

Title: Interpretation of Amyloid PET and Considerations for Quantitative Indicators in the Treatment of Anti-Amyloid Beta Antibodies.

Moderator: Kazunari Ishi MD PhD
Department of Radiation Diagnostics, Faculty of Medicine, Kindai University

Presenter: Kenji Ishii MD
Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology

Date: 12:00-12:50pm April 11, 2025 (JT)

Location: Conference Center, 3rd floor, 313+314

【Information on the exhibitor booth】

Under the theme of 'Total Solutions in Nuclear Medicine,' PDRadiopharma will showcase a variety of cutting-edge healthcare DX (Digital Transformation) products, including radiopharmaceutical products, the automatic injection system 'Bridgea INJECTOR,' and the latest features of the medical radiation dose management system 'onti', officially launched on March 31, 2025.

The booth will feature hands-on demonstrations using actual devices and demo data, allowing visitors to gain a realistic understanding of how these solutions can be implemented and operated in clinical settings.

We invite you to experience the future of nuclear medicine, brought to life through innovation and integration.

Booth location: Exhibition Hall, No.C2-04

Date: 10:00am - 5:00pm April 11, 2025 (JT)

9:30am - 5:00pm April 12, 2025 (JT)

9:30am - 3:00pm April 13, 2025 (JT)

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: s-info-hq@pdradiopharma.com